Pharmaceutical

TriSalus merges with MedTech Acquisition to bolster cash reserves

TriSalus is breaking into cancer therapeutics research with its TLR agonist SD-101 for treating solid tumours.

Aug 12, 2023 - 20:00
TriSalus merges with MedTech Acquisition to bolster cash reserves
TriSalus is breaking into cancer therapeutics research with its TLR agonist SD-101 for treating solid tumours.
Read the original article

Tags:

Previous Article

Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC

Next Article

Oxurion unlocks $1m from Atlas for diabetic macular oedema therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Key House Republican escalates rhetoric against PBMs

STAT+: Key House Republican escalates rhetoric against ...

Jun 14, 2023

Oxurion unlocks $1m from Atlas for diabetic macular oedema therapy

Oxurion unlocks $1m from Atlas for diabetic macular oed...

Aug 12, 2023

Does the hype around generative AI reflect its technology progress?

Does the hype around generative AI reflect its technolo...

Jul 5, 2023